Creo Medical Group (LSE:CREO) Tariff Resilience Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:CREO Creo Medical Group PLC LSE:CREO
52 GF Score
Price £0.14
GF Value £0.18
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Tariff Resilience Score?

Creo Medical Group has the Tariff Resilience Score of 0, which implies that the company might have .

Creo Medical Group has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Creo Medical Group might have .

Creo Medical Group  (LSE:CREO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Creo Medical Group Tariff Resilience Score Related Terms

LSE:CREO
52GF Score
Creo Medical Group PLC LSE:CREO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (LSE:CREO) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of £0.14 is trading 20.8% below its estimated GF Value™ of £0.18. GuruFocus considers Creo Medical Group to be Modestly Undervalued.

Key valuation signals for LSE:CREO:

  • Tariff Resilience Score: 0
  • GF Value™: £0.18 vs. price of £0.14 (20.8% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the LSE:CREO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score

Get the complete analysis for LSE:CREO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.14
Price
£0.18
GF Value